Jessica Cassavaugh, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stiff-Person Syndrome | 1 | 2016 | 32 | 0.510 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2016 | 144 | 0.490 |
Why?
|
| Neuromuscular Blockade | 1 | 2016 | 146 | 0.470 |
Why?
|
| Anesthetics, Intravenous | 1 | 2016 | 397 | 0.410 |
Why?
|
| Anesthetics, Inhalation | 1 | 2016 | 573 | 0.360 |
Why?
|
| F-Box Proteins | 1 | 2011 | 199 | 0.340 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 647 | 0.320 |
Why?
|
| Anesthesia, General | 1 | 2016 | 1172 | 0.310 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 618 | 0.290 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 1892 | 0.200 |
Why?
|
| Cytoskeletal Proteins | 3 | 2012 | 1325 | 0.180 |
Why?
|
| Early Ambulation | 1 | 2021 | 49 | 0.180 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 3430 | 0.170 |
Why?
|
| Paraplegia | 1 | 2020 | 158 | 0.170 |
Why?
|
| Spinal Cord Ischemia | 1 | 2020 | 92 | 0.160 |
Why?
|
| Androstanols | 1 | 2016 | 46 | 0.130 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2020 | 1090 | 0.120 |
Why?
|
| Drainage | 1 | 2020 | 1179 | 0.120 |
Why?
|
| Methyl Ethers | 1 | 2016 | 196 | 0.120 |
Why?
|
| Aortic Diseases | 1 | 2020 | 729 | 0.110 |
Why?
|
| Osteosarcoma | 2 | 2011 | 909 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 11888 | 0.100 |
Why?
|
| Fentanyl | 1 | 2016 | 457 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2020 | 4137 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2021 | 2966 | 0.090 |
Why?
|
| RNA | 1 | 2020 | 2717 | 0.090 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2020 | 1434 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2011 | 190 | 0.090 |
Why?
|
| Propofol | 1 | 2016 | 606 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 414 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2020 | 3141 | 0.080 |
Why?
|
| Critical Illness | 1 | 2021 | 2744 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2021 | 3461 | 0.070 |
Why?
|
| Myocardium | 1 | 2020 | 4760 | 0.070 |
Why?
|
| Ubiquitination | 1 | 2011 | 996 | 0.070 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 2222 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 2477 | 0.060 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 2086 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4562 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2008 | 1202 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2011 | 8278 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 3602 | 0.050 |
Why?
|
| Cytoskeleton | 1 | 2008 | 1178 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2011 | 4893 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2012 | 17075 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 5891 | 0.050 |
Why?
|
| Actins | 1 | 2008 | 2056 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 2631 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2011 | 2128 | 0.040 |
Why?
|
| Endoleak | 1 | 2020 | 111 | 0.040 |
Why?
|
| Oxygen | 1 | 2011 | 4241 | 0.040 |
Why?
|
| Ulcer | 1 | 2020 | 201 | 0.040 |
Why?
|
| Aneurysm, False | 1 | 2020 | 264 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2020 | 1644 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2021 | 637 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 2567 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 4900 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2020 | 1441 | 0.030 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2020 | 700 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 8611 | 0.030 |
Why?
|
| Autophagy | 1 | 2020 | 1351 | 0.020 |
Why?
|
| Female | 5 | 2021 | 396112 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 2415 | 0.020 |
Why?
|
| Humans | 9 | 2021 | 765968 | 0.020 |
Why?
|
| Microscopy, Video | 1 | 2011 | 241 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 870 | 0.020 |
Why?
|
| Middle Aged | 3 | 2021 | 223009 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3800 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 13451 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 1192 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3807 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2012 | 5020 | 0.010 |
Why?
|
| Apoptosis | 1 | 2020 | 9514 | 0.010 |
Why?
|
| Transfection | 1 | 2012 | 5743 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2011 | 3946 | 0.010 |
Why?
|
| Phenotype | 2 | 2012 | 16721 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 3797 | 0.010 |
Why?
|
| Aged | 3 | 2021 | 171117 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 3421 | 0.010 |
Why?
|
| Neoplasms | 1 | 2011 | 22340 | 0.010 |
Why?
|
| Gene Expression | 1 | 2011 | 7584 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2020 | 24282 | 0.010 |
Why?
|
| Time Factors | 1 | 2020 | 40065 | 0.010 |
Why?
|
| Male | 3 | 2021 | 363698 | 0.010 |
Why?
|
| Cell Line | 1 | 2012 | 15543 | 0.010 |
Why?
|
| Wound Healing | 1 | 2008 | 2792 | 0.010 |
Why?
|
| Cell Movement | 1 | 2008 | 5194 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 54802 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 59489 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 65188 | 0.010 |
Why?
|
| Risk Factors | 1 | 2020 | 74840 | 0.010 |
Why?
|
| Mice | 2 | 2011 | 81819 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 81514 | 0.010 |
Why?
|
| Animals | 2 | 2011 | 168764 | 0.000 |
Why?
|
| Mutation | 1 | 2011 | 30198 | 0.000 |
Why?
|
| Adult | 1 | 2021 | 223044 | 0.000 |
Why?
|